Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 79, Issue 3, Pages 535-543Publisher
SPRINGER
DOI: 10.1007/s00280-017-3248-2
Keywords
ANLN; Breast cancer; Anthracycline; Prognosis
Categories
Funding
- National Natural Science Foundation of China [81572612]
- Fundamental Research Funds for the Central Universities of Central South University [2015zzts116]
Ask authors/readers for more resources
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available